The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...
NICE guidance published today recommends leniolisib (also called Joenja and made by Pharming) for treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over.
Cost and evidence gaps remain barriers to approving funding in the NHS for donanemab and lecanemab. Today we’ve published further draft guidance for public consultation that continues to not recommend ...
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] Draft guidance Technology appraisal guidance 27 March ...
NICE is unable to make a recommendation about the use in the NHS of atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in ...
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
You can access a range of bibliographical databases with your NHS OpenAthens account. Sign in to see what you can access. You can access bibliographic databases from the providers' websites. For ...
This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this ...
Efanesoctocog alfa (also called Altuvoct and made by Swedish Orphan Biovitrum) can be given as a once-weekly injection instead of some current treatments that are given several times a week. Affecting ...
Final guidance published today recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma when ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee A. Committee members are asked to declare any interests in the technology being ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果